Advertisement
Table 1 Clinico-pathological parameters for patients with ET and early/prefibrotic PMF
| True ET | PMF | p value | |
|---|---|---|---|
| M/F | 27/34 | 26/46 | n.s. |
| Median age (years) | 58.0 (23–84) | 55.5 (20–87) | n.s. |
| Mean WBC (109/l) | 7.5 | 8.4 | p = 0.001 |
| Mean Hb (g/dl) | 14.1 | 14.3 | n.s. |
| Mean PLT (109/l) | 751 | 798 | n.s. |
| Increased LDH (%) | 17/45 (37.7%) | 18/50 (36.0%) | n.s. |
| Splenomegaly (%) | 12 (19%) | 18 (25%) | n.s. |
| Mean semiquantitative score for granulopoiesis | 0.15 | 1.02 | p = 0.001 |
| JAK2V617F-positive (%) | 11 (33%) | 23 (54%) | n.s. |
| History of thrombosis (%) | 5 (8%) | 16 (22%) | p = 0.032 |
| Thrombosis at diagnosis (%) | 1 (1.6%) | 11 (15.2%) | p = 0.006 |
| Thrombotic events during follow up (%) | 7 (11.4%) | 11 (15.2%) | n.s. |
| Progression to overt MF (%) | 1 (1.6%) | 3 (4.1%) | n.s. |
| Dead/alive | 2/59 | 8/64 | n.s. |
| Conventional Risk (Low/High) | 35/26 | 30/42 | n.s. |
| Cytoreductive therapy (%) | 51 (83%) | 64 (88%) | n.s. |
